Schroder Investment Management Group Purchases 196,823 Shares of Johnson & Johnson $JNJ

Key Points

• Schroder Investment Management Group increased its Johnson & Johnson position by 10.8%, buying 196,823 shares to hold 2,026,214 shares worth about $375.7 million per its latest 13F filing.
• Johnson & Johnson declared a quarterly dividend of $1.30 (annualized $5.20), implying a 2.2% yield, payable March 10 with an ex-dividend/record date of February 24.
• Insiders have been net sellers recently — EVP Timothy Schmid sold 22,623 shares and EVP Vanessa Broadhurst sold 6,197 shares, with insiders selling 30,142 shares totaling about $7.36 million over the last 90 days.

Schroder Investment Management Group boosted its position in Johnson & Johnson (NYSE:JNJ - Free Report) by 10.8% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,026,214 shares of the company's stock after purchasing an additional 196,823 shares during the quarter. Schroder Investment Management Group owned about 0.08% of Johnson & Johnson worth $375,701,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also recently made changes to their positions in the company. Abich Financial Wealth Management LLC bought a new stake in shares of Johnson & Johnson during the 3rd quarter valued at about $26,000. Evolution Wealth Management Inc. bought a new stake in Johnson & Johnson during the second quarter valued at approximately $27,000. Clayton Financial Group LLC bought a new position in shares of Johnson & Johnson in the 3rd quarter worth $28,000. Semmax Financial Advisors Inc. lifted its holdings in shares of Johnson & Johnson by 55.0% during the 2nd quarter. Semmax Financial Advisors Inc. now owns 203 shares of the company's stock worth $31,000 after acquiring an additional 72 shares during the last quarter. Finally, Compass Financial Services Inc increased its stake in Johnson & Johnson by 707.1% in the third quarter. Compass Financial Services Inc now owns 226 shares of the company's stock valued at $42,000 after acquiring an additional 198 shares during the last quarter. Institutional investors own 69.55% of the company's stock.

Johnson & Johnson Stock Performance

Shares of NYSE:JNJ opened at $240.57 on Monday. The company has a current ratio of 1.03, a quick ratio of 0.77 and a debt-to-equity ratio of 0.48. The company has a 50-day moving average price of $228.36 and a 200-day moving average price of $204.37. The company has a market cap of $579.75 billion, a price-to-earnings ratio of 21.77, a price-to-earnings-growth ratio of 2.37 and a beta of 0.34. Johnson & Johnson has a 12 month low of $141.50 and a 12 month high of $251.71.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings results on Saturday, January 31st. The company reported $2.46 earnings per share (EPS) for the quarter. The company had revenue of $24.28 billion for the quarter. Johnson & Johnson had a return on equity of 33.04% and a net margin of 28.46%. As a group, equities analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Investors of record on Tuesday, February 24th will be paid a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a yield of 2.2%. The ex-dividend date of this dividend is Tuesday, February 24th. Johnson & Johnson's dividend payout ratio is presently 47.06%.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on JNJ shares. JPMorgan Chase & Co. increased their price objective on Johnson & Johnson from $225.00 to $250.00 and gave the company a "neutral" rating in a research report on Thursday. Barclays boosted their price objective on shares of Johnson & Johnson from $197.00 to $217.00 and gave the stock an "equal weight" rating in a report on Tuesday, December 30th. Wolfe Research increased their target price on shares of Johnson & Johnson from $225.00 to $240.00 and gave the company an "outperform" rating in a report on Monday, January 5th. Scotiabank reissued an "outperform" rating on shares of Johnson & Johnson in a research note on Thursday, January 22nd. Finally, Bank of America reaffirmed a "neutral" rating on shares of Johnson & Johnson in a research note on Monday, March 2nd. One investment analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and nine have assigned a Hold rating to the company. According to MarketBeat, Johnson & Johnson has a consensus rating of "Moderate Buy" and a consensus target price of $234.87.

Insider Buying and Selling

In related news, EVP Timothy Schmid sold 22,623 shares of Johnson & Johnson stock in a transaction dated Wednesday, February 18th. The shares were sold at an average price of $244.33, for a total transaction of $5,527,477.59. Following the completion of the transaction, the executive vice president directly owned 26,769 shares of the company's stock, valued at $6,540,469.77. This trade represents a 45.80% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, EVP Vanessa Broadhurst sold 6,197 shares of the company's stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $243.39, for a total transaction of $1,508,287.83. Following the completion of the sale, the executive vice president owned 23,003 shares in the company, valued at approximately $5,598,700.17. This trade represents a 21.22% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 30,142 shares of company stock valued at $7,360,528. 0.16% of the stock is currently owned by company insiders.

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company's pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.